Agilent Technologies of Palo Alto, Calif., and Caliper Technologies of Mountain View, Calif., have jointly released a new version of the Agilent 2100 bioanalyzer system software for use with the Agilent 2100 bioanalyzer and Agilent LabChip kits.
New features include a new calibration feature, new alignment functionality, and a new software assay.
Shipments of the Agilent 2100 bioanalyzer systems including the new software revision began August 15. Current Agilent 2100 bioanalyzer users will receive a free update by mail.
The GeneTrove division of Carlsbad, Calif.-based Isis Pharmaceuticals has introduced its antisense technology-based Human Gene Function Database. According to Isis, users of the database will be able to discover the pharmacological effect of inhibiting individual genes.
The database will initially include data from nearly 1,000 genes and focus on oncology, angiogenesis, and inflammatory and metabolic diseases as therapeutic areas of investigation. By the end of the year, Isis expects to have identified antisense inhibitors to these genes and have data regarding the effect of specifically inhibiting the expression of these genes in more than 40 pharmacological assays. Within four years, Isis plans to include data on up to 10,000 genes as well as data from its recently announced gene functionalization collaboration with Celera Genomics.
The database will be made available to customers in quarterly data installments. Isis expects to deliver the first installment by the end of this year.
Gene Logic, based in Gaithersburg, Md., has launched the GeneExpress Human Atlas DataSuite, a survey of normal human gene expression that serves as a baseline reference source.
The Human Atlas DataSuite currently offers several thousand normal human samples, encompassing over 80 normal human organs and tissue types, and is expected to grow as the company continues to build its tissue repository.
The product also includes access to Gene Logics GeneExpress data management and analysis platform.